IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second ...

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

At this time, I would like to welcome everyone to the Karyopharm Therapeutics' call to discuss top line results from the Phase III SENTRY trial. There will be a question-and-answer session to follow.
Naturopathic Doctor News and Review

Hyperbaric Oxygen Therapy in Sports Medicine: Clinical Applications in Concussion and Musculoskeletal Injury

Joseph Thomas, MD, MBA, Fellow of Metabolic and Nutritional Medicine In collaboration with Oxygen Health Systems Abstract ...
MPR

Selinexor Combo Hits Spleen Target, Misses Symptom Endpoint in Myelofibrosis

Results from the phase 3 SENTRY trial show that selinexor plus ruxolitinib significantly reduced spleen volume in patients with myelofibrosis.
Scientific Research Publishing

A Multimodal Machine-Learning Framework for Predicting Lithium-Associated Renal Dysfunction from Synthetic Biomarker Trajectories ()

Long-term lithium therapy remains the most effective maintenance treatment for bipolar disorder, yet it poses a significant ...